BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tada T, Kumada T, Toyoda H, Mizuno K, Sone Y, Kataoka S, Hashinokuchi S. Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. J Gastroenterol Hepatol. 2017;32:1982-1988. [PMID: 28299813 DOI: 10.1111/jgh.13788] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 23.0] [Reference Citation Analysis]
Number Citing Articles
1 Wei H, Song B. Elastography for Longitudinal Assessment of Liver Fibrosis after Antiviral Therapy: A Review. J Clin Transl Hepatol 2020;8:445-53. [PMID: 33447528 DOI: 10.14218/JCTH.2020.00033] [Reference Citation Analysis]
2 Chen SH, Lai HC, Chiang IP, Su WP, Lin CH, Kao JT, Chuang PH, Hsu WF, Wang HW, Chen HY, Huang GT, Peng CY. Changes in liver stiffness measurement using acoustic radiation force impulse elastography after antiviral therapy in patients with chronic hepatitis C. PLoS One. 2018;13:e0190455. [PMID: 29293628 DOI: 10.1371/journal.pone.0190455] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
3 Lee HW, Oh SR, Kim DY, Jeong Y, Kim S, Kim BK, Kim SU, Kim DY, Ahn SH, Han KH, Park JY. Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety. Gut Liver 2018;12:324-30. [PMID: 29409309 DOI: 10.5009/gnl17298] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
4 Yeh ML, Huang CF, Huang CI, Hsieh MY, Hou NJ, Lin IH, Liang PC, Tsai YS, Hsieh MH, Lin ZY, Chen SC, Dai CY, Huang JF, Yu ML, Chuang WL. The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment. Kaohsiung J Med Sci 2019;35:624-32. [PMID: 31254328 DOI: 10.1002/kjm2.12105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
5 Fujii H, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Nakamura H, Yasui K, Minami M, Tanaka S, Ishikawa H, Kimura H, Takami S, Nagao Y, Shima T, Itoh Y. Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions. World J Hepatol 2017; 9(25): 1064-1072 [PMID: 28951778 DOI: 10.4254/wjh.v9.i25.1064] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
6 Elabd NS, Tayel SI, Elhamouly MS, Hassanein SA, Kamaleldeen SM, Ahmed FE, Rizk M, Gadallah AA, Ajlan SE, Sief AS. Evaluation of MicroRNA-122 as a Biomarker for Chronic Hepatitis C Infection and as a Predictor for Treatment Response to Direct-Acting Antivirals. Hepat Med 2021;13:9-23. [PMID: 33758557 DOI: 10.2147/HMER.S292251] [Reference Citation Analysis]
7 Lim EJ, Torresi J. Prevention of Hepatitis C Virus Infection and Liver Cancer. Recent Results Cancer Res 2021;217:107-40. [PMID: 33200364 DOI: 10.1007/978-3-030-57362-1_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Levy S, Samuel D. Prevention of decompensation in cirrhosis: a new youth for β blockers. The Lancet 2019;393:1571-2. [DOI: 10.1016/s0140-6736(19)30736-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Peschel G, Grimm J, Buechler C, Gunckel M, Pollinger K, Aschenbrenner E, Kammerer S, Jung EM, Haimerl M, Werner J, Müller M, Weigand K. Liver stiffness assessed by shear-wave elastography declines in parallel with immunoregulatory proteins in patients with chronic HCV infection during DAA therapy. Clin Hemorheol Microcirc 2021. [PMID: 34120896 DOI: 10.3233/CH-211193] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Garg G, Dixit VK, Shukla SK, Singh SK, Sachan S, Tiwari A, Yadav VK, Yadav DP. Impact of Direct Acting Antiviral Drugs in Treatment Naïve HCV Cirrhosis on Fibrosis and Severity of Liver Disease: A Real Life Experience from a Tertiary Care Center of North India. J Clin Exp Hepatol 2018;8:241-9. [PMID: 30302040 DOI: 10.1016/j.jceh.2017.11.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
11 Sangineto M, Luglio CV, Mastrofilippo T, Zingaro MT, Berardi E, Antonica G, Sabbà C, Napoli N. Analysis of hepatic stiffness after viral eradication in a population with chronic hepatitis C treated with DAAs. Med Clin (Barc) 2021;156:317-23. [PMID: 32788043 DOI: 10.1016/j.medcli.2020.04.050] [Reference Citation Analysis]
12 Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Michitaka K, Deguchi A, Ishikawa T, Imai M, Ochi H, Joko K, Shimada N, Tajiri K, Hirooka M, Koizumi Y, Hiasa Y, Tanaka J. Impact of albumin–bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time‐dependent receiver operating characteristic. Journal of Gastroenterology and Hepatology 2018;34:1066-73. [DOI: 10.1111/jgh.14564] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
13 Fabbri G, Mastrorosa I, Vergori A, Timelli L, Lorenzini P, Zaccarelli M, Cicalini S, Bellagamba R, Plazzi MM, Mazzotta V, Antinori A, Ammassari A. Liver stiffness reduction and serum fibrosis score improvement in HIV/hepatitis C virus-coinfected patients treated with direct-acting antivirals. HIV Med 2018. [PMID: 29953713 DOI: 10.1111/hiv.12632] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
14 Chan J, Gogela N, Zheng H, Lammert S, Ajayi T, Fricker Z, Kim AY, Robbins GK, Chung RT. Direct-Acting Antiviral Therapy for Chronic HCV Infection Results in Liver Stiffness Regression Over 12 Months Post-treatment. Dig Dis Sci 2018;63:486-92. [PMID: 28887750 DOI: 10.1007/s10620-017-4749-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 9.5] [Reference Citation Analysis]
15 Cerrito L, Ainora ME, Nicoletti A, Garcovich M, Riccardi L, Pompili M, Gasbarrini A, Zocco MA. Elastography as a predictor of liver cirrhosis complications after hepatitis C virus eradication in the era of direct-acting antivirals. World J Hepatol 2021; 13(11): 1663-1676 [DOI: 10.4254/wjh.v13.i11.1663] [Reference Citation Analysis]
16 Sugimoto R, Iwasa M, Hara N, Tamai Y, Yoshikawa K, Ogura S, Tanaka H, Eguchi A, Yamamoto N, Kobayashi Y, Hasegawa H, Takei Y. Changes in liver function and body composition by direct-acting antiviral therapy for hepatitis C virus infection. Hepatol Res 2018;48:337-44. [PMID: 29115717 DOI: 10.1111/hepr.12999] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
17 Zhang YN, Fowler KJ, Ozturk A, Potu CK, Louie AL, Montes V, Henderson WC, Wang K, Andre MP, Samir AE, Sirlin CB. Liver fibrosis imaging: A clinical review of ultrasound and magnetic resonance elastography. J Magn Reson Imaging 2020;51:25-42. [PMID: 30859677 DOI: 10.1002/jmri.26716] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
18 Jeong JY, Cho YS, Sohn JH. Role of two-dimensional shear wave elastography in chronic liver diseases: A narrative review. World J Gastroenterol 2018; 24(34): 3849-3860 [PMID: 30228779 DOI: 10.3748/wjg.v24.i34.3849] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
19 Tada T, Kumada T, Toyoda H, Yasuda S, Koyabu T, Nakashima M. Impact of Branched-Chain Amino Acid Granule Therapy in Patients with Hepatocellular Carcinoma Who Have Normal Albumin Levels and Low Branched-Chain Amino Acid to Tyrosine Ratios. Nutr Cancer 2019;71:1132-41. [PMID: 30955354 DOI: 10.1080/01635581.2019.1597905] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
20 Dash S, Aydin Y, Wu T. Integrated stress response in hepatitis C promotes Nrf2-related chaperone-mediated autophagy: A novel mechanism for host-microbe survival and HCC development in liver cirrhosis. Semin Cell Dev Biol 2020;101:20-35. [PMID: 31386899 DOI: 10.1016/j.semcdb.2019.07.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
21 Ponziani FR, Putignani L, Paroni Sterbini F, Petito V, Picca A, Del Chierico F, Reddel S, Calvani R, Marzetti E, Sanguinetti M, Gasbarrini A, Pompili M. Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis. Aliment Pharmacol Ther 2018;48:1301-11. [PMID: 30345704 DOI: 10.1111/apt.15004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
22 Chen S, Peng C. Ultrasound-Based Liver Stiffness Surveillance in Patients Treated for Chronic Hepatitis B or C. Applied Sciences 2018;8:626. [DOI: 10.3390/app8040626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Oh JY, Kim BS, Lee CH, Song JE, Lee HJ, Park JG, Hwang JS, Chung WJ, Jang BK, Kweon YO, Tak WY, Park SY, Jang SY, Suh JI, Kwak SG. Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world. Korean J Intern Med 2019;34:794-801. [PMID: 29792020 DOI: 10.3904/kjim.2017.368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
24 Yamazaki T, Joshita S, Umemura T, Usami Y, Sugiura A, Fujimori N, Kimura T, Matsumoto A, Igarashi K, Ota M, Tanaka E. Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C. PLoS One 2018;13:e0195632. [PMID: 29617443 DOI: 10.1371/journal.pone.0195632] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
25 Kang Q, Xu J, Luo H, Tan N, Chen H, Cheng R, Pan J, Han Y, Yang Y, Liu D, Xi H, Yu M, Xu X. Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication. J Viral Hepat 2021;28:1284-92. [PMID: 34105867 DOI: 10.1111/jvh.13558] [Reference Citation Analysis]
26 Malin JJ, Boesecke C, Schwarze-Zander C, Wasmuth JC, Schlabe S, Trebicka J, Spengler U, Llibre JM, Jou T, Vasylyev M, Clotet B, Rockstroh JK. Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection. HIV Med 2019;20:230-6. [PMID: 30687989 DOI: 10.1111/hiv.12705] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
27 Pan JJ, Bao F, Du E, Skillin C, Frenette CT, Waalen J, Alaparthi L, Goodman ZD, Pockros PJ. Morphometry Confirms Fibrosis Regression From Sustained Virologic Response to Direct-Acting Antivirals for Hepatitis C. Hepatol Commun 2018;2:1320-30. [PMID: 30411079 DOI: 10.1002/hep4.1228] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 9.7] [Reference Citation Analysis]
28 Hill LA, Delmonte RJ, Andrews B, Richards L, Soto R, Collier S, Kuo A, Cachay E. Treatment of hepatitis C with direct-acting antivirals significantly reduces liver-related hospitalizations in patients with cirrhosis. Eur J Gastroenterol Hepatol 2018;30:1378-83. [PMID: 29975243 DOI: 10.1097/MEG.0000000000001195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
29 Lee SH, Shin HP, Lee JI. Real-world single-center experience with direct-acting antivirals for improvement of the liver fibrosis after chronic hepatitis C treatment. Antivir Chem Chemother 2020;28:2040206620974835. [PMID: 33215505 DOI: 10.1177/2040206620974835] [Reference Citation Analysis]
30 Argalia G, Tarantino G, Ventura C, Campioni D, Tagliati C, Guardati P, Kostandini A, Marzioni M, Giuseppetti GM, Giovagnoni A. Shear wave elastography and transient elastography in HCV patients after direct-acting antivirals. Radiol Med 2021;126:894-9. [PMID: 33492651 DOI: 10.1007/s11547-020-01326-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Muñoz-Hernández R, Ampuero J, Millán R, Gil-Gómez A, Rojas Á, Macher HC, Gallego-Durán R, Gato S, Montero-Vallejo R, Rico MC, Maya-Miles D, Sánchez-Torrijos Y, Soria IC, Stiefel P, Romero-Gómez M. Hepatitis C Virus Clearance by Direct-Acting Antivirals Agents Improves Endothelial Dysfunction and Subclinical Atherosclerosis: HEPCAR Study. Clin Transl Gastroenterol 2020;11:e00203. [PMID: 32955194 DOI: 10.14309/ctg.0000000000000203] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
32 Knop V, Mauss S, Goeser T, Geier A, Zimmermann T, Herzer K, Postel N, Friedrich-Rust M, Hofmann WP; German Hepatitis C-Registry. Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-Results from the German Hepatitis C-Registry. J Viral Hepat 2020;27:690-8. [PMID: 32096310 DOI: 10.1111/jvh.13280] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
33 Trivedi HD, Patwardhan VR, Malik R. Chronic hepatitis C infection — Noninvasive assessment of liver fibrosis in the era of direct acting antivirals. Digestive and Liver Disease 2019;51:183-9. [DOI: 10.1016/j.dld.2018.11.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
34 Wei L, Huang YH. Long-term outcomes in patients with chronic hepatitis C in the current era of direct-acting antiviral agents. Expert Rev Anti Infect Ther 2019;17:311-25. [PMID: 30856022 DOI: 10.1080/14787210.2019.1588112] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
35 Paternostro R, Pfeiffenberger J, Ferenci P, Stättermayer AF, Stauber RE, Wrba F, Longerich T, Lackner K, Trauner M, Ferlitsch A, Reiberger T, Weiss KH. Non-invasive diagnosis of cirrhosis and long-term disease monitoring by transient elastography in patients with Wilson disease. Liver Int 2020;40:894-904. [PMID: 31898387 DOI: 10.1111/liv.14368] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
36 Fahmy DM, Shokeir M, El Zeiny SM, Jonas MM, Abdallah A. Changes in Liver Stiffness and Noninvasive Fibrosis Scores in Egyptian Adolescents Successfully Treated with Ledipasvir-Sofosbuvir for Chronic Hepatitis C Virus Infection. J Pediatr 2021;231:110-6. [PMID: 33347957 DOI: 10.1016/j.jpeds.2020.12.031] [Reference Citation Analysis]
37 Zakareya T, Elhelbawy M, Elzohry H, Eltabbakh M, Deif M, Abbasy M. Long-Term Impact of Hepatitis C Virus Eradication on Liver Stiffness in Egyptian Patients. Can J Gastroenterol Hepatol 2021;2021:4961919. [PMID: 34589447 DOI: 10.1155/2021/4961919] [Reference Citation Analysis]
38 Endo K, Sato T, Suzuki A, Yoshida Y, Kakisaka K, Miyasaka A, Takikawa Y. Sustained virologic response by direct-acting antivirals suppresses skeletal muscle loss in hepatitis C virus infection. J Gastroenterol Hepatol. 2020;35:1602-1609. [PMID: 31975438 DOI: 10.1111/jgh.14991] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
39 Mihăilă RG. Liver stiffness in chronic hepatitis C virus infection. Rom J Intern Med 2019;57:85-98. [PMID: 30447147 DOI: 10.2478/rjim-2018-0034] [Reference Citation Analysis]
40 Kohla MAS, Fayoumi AE, Akl M, Abdelkareem M, Elsakhawy M, Waheed S, Abozeid M. Early fibrosis regression by shear wave elastography after successful direct-acting anti-HCV therapy. Clin Exp Med 2020;20:143-8. [PMID: 31792631 DOI: 10.1007/s10238-019-00597-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
41 Ridziauskas M, Zablockienė B, Jančorienė L, Samuilis A, Zablockis R, Jackevičiūtė A. Assessment of Liver Stiffness Regression and Hepatocellular Carcinoma Risk in Chronic Hepatitis C Patients after Treatment with Direct-Acting Antiviral Drugs. Medicina (Kaunas) 2021;57:210. [PMID: 33652777 DOI: 10.3390/medicina57030210] [Reference Citation Analysis]
42 Stasi C, Sadalla S, Carradori E, Monti M, Petraccia L, Madia F, Gragnani L, Zignego AL. Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment. Curr Med Res Opin 2020;36:245-9. [PMID: 31702411 DOI: 10.1080/03007995.2019.1691517] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
43 Kronfli N, Young J, Wang S, Cox J, Walmsley S, Hull M, Cooper C, Martel-Laferriere V, Wong A, Pick N, Klein MB; Canadian Coinfection Cohort Study Investigators. Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression? Clin Infect Dis 2021;73:468-77. [PMID: 32504083 DOI: 10.1093/cid/ciaa702] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
44 Alem SA, Said M, Anwar I, Abdellatif Z, Elbaz T, Eletreby R, AbouElKhair M, El-Serafy M, Mogawer S, El-Amir M, El-Shazly M, Hosny A, Yosry A. Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort. J Med Virol 2018;90:1508-15. [PMID: 29718546 DOI: 10.1002/jmv.25210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
45 Giannini EG, Crespi M, Demarzo M, Bodini G, Furnari M, Marabotto E, Torre F, Zentilin P, Savarino V. Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals. Eur J Clin Invest. 2019;49:e13056. [PMID: 30474209 DOI: 10.1111/eci.13056] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
46 Flisiak R, Janczewska E, Łucejko M, Karpińska E, Zarębska-Michaluk D, Nazzal K, Bolewska B, Białkowska J, Berak H, Fleischer-Stępniewska K, Tomasiewicz K, Karwowska K, Simon K, Piekarska A, Tronina O, Tuchendler E, Garlicki A. Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study. J Viral Hepat 2018;25:1298-305. [PMID: 29888828 DOI: 10.1111/jvh.12945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
47 Omar H, Said M, Eletreby R, Mehrez M, Bassam M, Abdellatif Z, Hosny A, Megawer S, El Amir M, Yosry A. Longitudinal assessment of hepatic fibrosis in responders to direct-acting antivirals for recurrent hepatitis C after liver transplantation using noninvasive methods. Clin Transplant 2018;32:e13334. [PMID: 29935046 DOI: 10.1111/ctr.13334] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
48 Nozaki A, Chuma M, Hara K, Moriya S, Fukuda H, Numata K, Tanaka K, Morimoto M, Sakamaki K, Yamanaka T, Kondo M, Maeda S. Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection: A prospective observational study. Medicine (Baltimore) 2021;100:e25110. [PMID: 33761674 DOI: 10.1097/MD.0000000000025110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Tachi Y, Hirai T, Kojima Y, Tachino H, Hosokawa C, Ohya T, Yasue Y, Kurokawa Y, Torii Y, Yamamoto S, Matsuura H, Kobayashi T, Miyoshi H, Inui K, Katano Y. Diagnostic performance of real-time tissue elastography in chronic hepatitis C patients with sustained virological response. Eur J Gastroenterol Hepatol. 2020;32:609-615. [PMID: 31688308 DOI: 10.1097/meg.0000000000001539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Kobayashi N, Iijima H, Tada T, Kumada T, Yoshida M, Aoki T, Nishimura T, Nakano C, Takata R, Yoh K, Ishii A, Takashima T, Sakai Y, Aizawa N, Nishikawa H, Ikeda N, Iwata Y, Enomoto H, Hirota S, Fujimoto J, Nishiguchi S. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. Eur J Gastroenterol Hepatol 2018;30:546-51. [PMID: 29494353 DOI: 10.1097/MEG.0000000000001106] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
51 Iijima H, Tada T, Kumada T, Kobayashi N, Yoshida M, Aoki T, Nishimura T, Nakano C, Ishii A, Takashima T, Sakai Y, Aizawa N, Nishikawa H, Ikeda N, Iwata Y, Enomoto H, Ide Y, Hirota S, Fujimoto J, Nishiguchi S. Comparison of liver stiffness assessment by transient elastography and shear wave elastography using six ultrasound devices. Hepatol Res 2019;49:676-86. [DOI: 10.1111/hepr.13319] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
52 El-Garem H, AbdAllah M, Omar H, Cordie A, Abdel Alem S, Mohey Eldin Elzahry MA, Ghaith D, Abou El-Soud NH, Kamal W, Elsharkawy A, Esmat G. DAAs therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV. Expert Rev Gastroenterol Hepatol 2019;13:693-8. [PMID: 31043104 DOI: 10.1080/17474124.2019.1614441] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
53 Tachi Y, Hirai T, Kojima Y, Ishizu Y, Honda T, Kuzuya T, Hayashi K, Ishigami M, Goto H. Liver stiffness measurement predicts hepatocellular carcinoma development in patients treated with direct-acting antivirals. JGH Open 2017;1:44-9. [PMID: 30483532 DOI: 10.1002/jgh3.12007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
54 Calvaruso V, Cacciola I, Licata A, Madonia S, Benigno R, Petta S, Bronte F, Conte E, Malizia G, Bertino G, Distefano M, Montineri A, Digiacomo A, Alaimo G, Cacopardo B, Davì A, Guarneri L, Scalisi I, Colletti P, Cartabellotta F, Portelli V, Prestileo T, Averna A, Iacobello C, Mondello L, Scifo G, Russello M, Squadrito G, Raimondo G, Cammà C, Craxì A, Di Marco V; RESIST-HCV (Rete Sicilia Selezione Terapia–HCV). Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience. Am J Gastroenterol 2019;114:1275-82. [PMID: 31135449 DOI: 10.14309/ajg.0000000000000266] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]
55 Akuta N, Toyota J, Karino Y, Ikeda F, Ido A, Tanaka K, Takaguchi K, Naganuma A, Tomita E, Chayama K, Fujiyama S, Inada Y, Yoshiji H, Watanabe H, Ishikawa H, McPhee F, Noviello S, Kumada H. Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection. J Gastroenterol 2018;53:1089-97. [PMID: 29500489 DOI: 10.1007/s00535-018-1445-3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
56 Maekawa S, Sato M, Kuratomi N, Inoue T, Suzuki Y, Tatsumi A, Miura M, Matsuda S, Muraoka M, Nakakuki N, Amemiya F, Takano S, Fukasawa M, Nakayama Y, Yamaguchi T, Sato T, Sakamoto M, Murakawa M, Nakagawa M, Asahina Y, Enomoto N. Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C. J Gastroenterol 2018;53:780-6. [PMID: 29094205 DOI: 10.1007/s00535-017-1405-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
57 Tachi Y, Hirai T, Kojima Y, Ishizu Y, Honda T, Kuzuya T, Hayashi K, Ishigami M, Goto H, Katano Y. Predictive ability of shear wave elastography for pruritus in chronic hepatitis C patients with sustained virological response. European Journal of Gastroenterology & Hepatology 2018;30:1066-72. [DOI: 10.1097/meg.0000000000001159] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
58 Marticorena Garcia SR, Althoff CE, Dürr M, Halleck F, Budde K, Grittner U, Burkhardt C, Jöhrens K, Braun J, Fischer T, Hamm B, Sack I, Guo J. Tomoelastography for Longitudinal Monitoring of Viscoelasticity Changes in the Liver and in Renal Allografts after Direct-Acting Antiviral Treatment in 15 Kidney Transplant Recipients with Chronic HCV Infection. J Clin Med 2021;10:510. [PMID: 33535495 DOI: 10.3390/jcm10030510] [Reference Citation Analysis]
59 Sadeghi A, Amiri R, Akbarpour E, Mirminachi B, Sharifi AH, Merat S. Changes in liver fibrosis in patients with chronic hepatitis C after successful direct-acting antiviral therapy. Int J Clin Pract 2021;75:e14145. [PMID: 33709413 DOI: 10.1111/ijcp.14145] [Reference Citation Analysis]
60 Florea M, Serban T, Tirpe GR, Tirpe A, Lupsor-Platon M. Noninvasive Assessment of Hepatitis C Virus Infected Patients Using Vibration-Controlled Transient Elastography. J Clin Med 2021;10:2575. [PMID: 34200885 DOI: 10.3390/jcm10122575] [Reference Citation Analysis]
61 Yaraş S, Sezgin O, Üçbilek E, Özdoğan O, Altıntaş E. Significant decrease in liver stiffness detected by two dimensional shear-wave elastography after treatment with direct-acting antiviral agents in patients with chronic Hepatitis C. Turk J Gastroenterol 2020;31:142-7. [PMID: 32141823 DOI: 10.5152/tjg.2020.19418] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
62 Lledó G, Benítez-Gutiérrez L, Arias A, Requena S, Cuervas-Mons V, de Mendoza C. Benefits of hepatitis C cure with antivirals: why test and treat? Future Microbiol 2019;14:425-35. [PMID: 30900911 DOI: 10.2217/fmb-2019-0041] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]